Physician profile
Mukesh Jain
NPI 1447282991
$6,680.64
in general payments reported to CMS, 2019-2025
52 companies · $639 in 2025
The $639 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,413 · 2020: $1,135 · 2021: $1,479 · 2022: $168 · 2023: $885 · 2024: $962 · 2025: $639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,474 · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,474.48 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $800.00 | 2021 | |
| Novo Nordisk INC | $780.58 | 2019-2025 | Ozempic, Rybelsus, Saxenda |
| Lilly USA, LLC | $650.57 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $594.84 | 2019-2025 | Airsupra, Farxiga, Lokelma |
| Glaxosmithkline, LLC. | $467.69 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $357.58 | 2019-2025 | Jardiance |
| Abbott Laboratories | $279.03 | 2020-2025 | Freestyle Libre, Freestyle Libre 3, Eterna |
| Janssen Pharmaceuticals, INC | $259.62 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $175.19 | 2019-2023 | Belsomra, Verquvo |
| Amgen INC. | $155.28 | 2020-2025 | Repatha, Otezla, Evenity |
| Sanofi-Aventis U.S. LLC | $142.22 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $126.76 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $124.67 | 2023-2025 | |
| Pfizer INC. | $118.87 | 2019-2024 | |
| Astellas Pharma US INC | $115.38 | 2019-2025 | Veozah, Myrbetriq |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mukesh Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.